论文部分内容阅读
目的:研究CD117和CD34在成人急性非淋巴细胞白血病(Acute non lymphob lastic leukem ia,ANLL)M1~M2型和急性早幼粒细胞白血病(Acute promyelocytic leukem ia,APL)M3患者中的表达,重点探讨M3患者CD117和CD34共表达(CD117/CD34共表达)的临床意义。方法:将研究病例分为M1~M2和M3二组,采用流式细胞术(F low cytom etery,FCM)随机检测54例M3和63例M1~M2二组初诊患者骨髓单个核细胞(BMMNC)髓系抗原CD117和干(祖)细胞抗原CD34的表达;比较M1~M2和M3二组ANLL患者中CD117、CD34表达的阳性率的差异,以及CD13、CD33和CD117分别与CD34共表达的阳性率差异。结果:CD117在M1~M2组患者中表达的阳性率是71.4/%(45/63),在M3组表达的阳性率为66.7%(36/54),差异无统计学意义(P=0.58);CD34在M1~M2和M3二组中表达的阳性率分别为66.7%(42/63)和11.1%(6/54),差异有统计学意义(P=0.000);二组ANLL的CD117/CD34共表达阳性率分别为71.1%(45/63)和7.4%(4/54),其差异有统计学意义(P=0.000)。结论:CD117可作为AL的髓系免疫学标志,但其在ANLL中的表达缺乏系列内阶段特异性。M3患者的CD34表达和CD117/CD34共表达的阳性率低于M1~M2者;CD117/CD34共表达可作为M1~M2和M3鉴别诊断的免疫学分型参考指标。
Objective: To investigate the expression of CD117 and CD34 in adult patients with acute non-lymphoblastic leukemia (ANLL) M1-M2 and acute promyelocytic leukemia (APL) M3 The clinical significance of co-expression of CD117 and CD34 in M3 patients (co-expression of CD117 / CD34). Methods: The study was divided into two groups: M1 ~ M2 and M3. BMMNC was detected in 54 patients with M3 and 63 patients with M1 ~ M2 newly diagnosed by flow cytometry (F low cytom etery, FCM) Myeloid antigen CD117 and dry (progenitor) cell antigen CD34 expression; compared M1 ~ M2 and M3 two groups of ANLL patients CD117, CD34 expression of the positive rate differences, as well as CD13, CD33 and CD117 were co-expression of CD34 positive rate difference. Results: The positive expression rate of CD117 in M1 ~ M2 group was 71.4% (45/63), while the positive expression rate in M3 group was 66.7% (36/54), with no significant difference (P = 0.58) ; The positive rates of CD34 expression in M1 ~ M2 and M3 two groups were 66.7% (42/63) and 11.1% (6/54) respectively, the difference was statistically significant (P = 0.000); The positive rates of CD117 / The positive rates of CD34 expression were 71.1% (45/63) and 7.4% (4/54), respectively, with significant difference (P = 0.000). Conclusion: CD117 can be used as a marker of myeloid immunology in AL. However, its expression in ANLL lacks a series of intra-stage specificities. The positive rate of CD34 expression and CD117 / CD34 co-expression in M3 patients was lower than that in M1-M2 patients. CD117 / CD34 co-expression could be used as a reference marker for differential diagnosis of M1 ~ M2 and M3.